Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566307 | 0.89 | NISCH (0.50) | MAOBNISCHS1PR1MC4R | |
| Hydrochloric Acid SCHEMBL23880715 | 0.88 | NISCH (0.49) | MAOBNISCHS1PR1MC4R | |
| SCHEMBL23902210 | 0.88 | MAOB (0.48) | MAOBPRSS1F10MRGPRX1 | |
| SCHEMBL23901867 | 0.88 | F10 (0.43) | F10NISCH | |
| SCHEMBL23901804 | 0.83 | RUVBL1 (0.44) | MAOBNISCHS1PR1MC4R | |
| SCHEMBL23566125 | 0.83 | PRSS1 (0.62) | PRSS1F10MRGPRX1 | |
| Hydrochloric Acid SCHEMBL23880716 | 0.83 | RUVBL1 (0.44) | MAOBNISCHS1PR1MC4R | |
| Hydrochloric Acid SCHEMBL23235840 | 0.82 | PRSS1 (0.63) | PRSS1F10MRGPRX1 | |
| SCHEMBL23901795 | 0.81 | PIK3CG (0.44) | MAOBNISCHS1PR1MC4R | |
| SCHEMBL23901864 | 0.81 | F2 (0.51) | MAOBPRSS1F10NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MAOB 2311/4885PRSS1 652/4885F10 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.